Literature DB >> 28162121

Molecular approaches for HPV genotyping and HPV-DNA physical status.

D Tsakogiannis1, C Gartzonika2, S Levidiotou-Stefanou2, P Markoulatos1.   

Abstract

Persistent infection with high-risk human papillomavirus (HPV) genotypes is the leading cause of cervical cancer development. To this end several studies have focused on designing molecular assays for HPV genotyping, which are considered as the gold standard for the early diagnosis of HPV infection. Moreover, the tendency of HPV DNA to be integrated into the host chromosome is a determining event for cervical oncogenesis. Thus, the establishment of molecular techniques was promoted in order to investigate the physical status of the HPV DNA and the locus of viral insertion into the host chromosome. The molecular approaches that have been developed recently facilitate the collection of a wide spectrum of valuable information specific to each individual patient and therefore can significantly contribute to the establishment of a personalised prognosis, diagnosis and treatment of HPV-positive patients. The present review focuses on state of the art molecular assays for HPV detection and genotyping for intra-lesion analyses, it examines molecular approaches for the determination of HPV-DNA physical status and it discusses the criteria for selecting the most appropriate regions of viral DNA to be incorporated in HPV genotyping and in the determination of HPV-DNA physical status.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28162121     DOI: 10.1017/erm.2017.2

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  9 in total

Review 1.  The Involvement of Human Papilloma Virus in Gastrointestinal Cancers.

Authors:  Jacek Baj; Alicja Forma; Iga Dudek; Zuzanna Chilimoniuk; Maciej Dobosz; Michał Dobrzyński; Grzegorz Teresiński; Grzegorz Buszewicz; Jolanta Flieger; Piero Portincasa
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

Review 2.  Human Papillomavirus Infections, Cervical Cancer and MicroRNAs: An Overview and Implications for Public Health.

Authors:  Michela Lucia Sammarco; Manuela Tamburro; Alessandra Pulliero; Alberto Izzotti; Giancarlo Ripabelli
Journal:  Microrna       Date:  2020

3.  In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.

Authors:  Matin Kayyal; Azam Bolhassani; Zahra Noormohammadi; Majid Sadeghizadeh
Journal:  Mol Biotechnol       Date:  2021-07-25       Impact factor: 2.695

4.  Screening for Human Papillomavirus in a Low- and Middle-Income Country.

Authors:  Aaron E Atkinson; Carlos Alberto Matute Mandujano; Suyapa Bejarano; Linda S Kennedy; Gregory J Tsongalis
Journal:  J Glob Oncol       Date:  2019-05

5.  HRRD: a manually-curated database about the regulatory relationship between HPV and host RNA.

Authors:  Bingqing Yan; Siwei Zhang; Siyang Yu; Sajjad Hussain; Tianyang Liu; Bozhi Wang; Xiaoyu Dong; Fen Ma; Lanlan Wei
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

6.  A Sample-In-Answer-Out Microfluidic System for the Molecular Diagnostics of 24 HPV Genotypes Using Palm-Sized Cartridge.

Authors:  Rui Wang; Jing Wu; Xiaodong He; Peng Zhou; Zuojun Shen
Journal:  Micromachines (Basel)       Date:  2021-03-04       Impact factor: 2.891

7.  The correlation of HPV16 and HPV18 with local vaginal immunity after the treatment of cervical intraepithelial neoplasia.

Authors:  Lin Mu; Jing-Rui Miao; Jing-Hui Song
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

Review 8.  Molecular Pathology of Human Papilloma Virus-Negative Cervical Cancers.

Authors:  Hiroshi Yoshida; Kouya Shiraishi; Tomoyasu Kato
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

9.  Cervical Intraepithelial Neoplasia Grade 3 in a HPV-Vaccinated Patient: A Case Report.

Authors:  Mateja Sladič; Pepita Taneska; Branko Cvjetičanin; Mojca Velikonja; Vladimir Smrkolj; Špela Smrkolj
Journal:  Medicina (Kaunas)       Date:  2022-02-23       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.